Q-omics provides the consensus-scored ELOCP29 profile across patient tissues and cancer cell-line models. ELOCP29 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, ELOCP29 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, ELOCP29 RNA expression shows 6,320 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, HNSC, and STAD as cancer lineages where ELOCP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP29 survival associations across molecular data types. ELOCP29 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP29 RNA expression–survival associations across cancer types. High ELOCP29 expression shows unfavorable associations in CHOL, THCA and READ, but favorable associations in BLCA, LAML and LUSC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for ELOCP29 RNA expression.
This table summarizes ELOCP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP29 shows higher tumor expression in HNSC. The HNSC box plot shows higher ELOCP29 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .047).
This table shows molecular features associated with ELOCP29 in patient tissues and cancer cell lines. In patient samples, ELOCP29 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
